Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP219595.RADr9l1wZK9vl7GGRN-zKSbz4kqDjLCoVssOgcAuANRzI130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP219595.RADr9l1wZK9vl7GGRN-zKSbz4kqDjLCoVssOgcAuANRzI130_assertion type Assertion NP219595.RADr9l1wZK9vl7GGRN-zKSbz4kqDjLCoVssOgcAuANRzI130_head.
- NP219595.RADr9l1wZK9vl7GGRN-zKSbz4kqDjLCoVssOgcAuANRzI130_assertion wasGeneratedBy ECO_0000203 NP219595.RADr9l1wZK9vl7GGRN-zKSbz4kqDjLCoVssOgcAuANRzI130_provenance.
- NP219595.RADr9l1wZK9vl7GGRN-zKSbz4kqDjLCoVssOgcAuANRzI130_assertion wasDerivedFrom befree-20150227 NP219595.RADr9l1wZK9vl7GGRN-zKSbz4kqDjLCoVssOgcAuANRzI130_provenance.
- NP219595.RADr9l1wZK9vl7GGRN-zKSbz4kqDjLCoVssOgcAuANRzI130_assertion SIO_000772 15857289 NP219595.RADr9l1wZK9vl7GGRN-zKSbz4kqDjLCoVssOgcAuANRzI130_provenance.
- NP219595.RADr9l1wZK9vl7GGRN-zKSbz4kqDjLCoVssOgcAuANRzI130_assertion evidence source_evidence_literature NP219595.RADr9l1wZK9vl7GGRN-zKSbz4kqDjLCoVssOgcAuANRzI130_provenance.
- NP219595.RADr9l1wZK9vl7GGRN-zKSbz4kqDjLCoVssOgcAuANRzI130_assertion description "[This assumption has been derived by the successful development of BCR/ABL tyrosine kinase inhibitors in human chronic myeloid leukemia as well as on the activity of antiCD20 monoclonal antibodies in lymphoproliferative disease and of anti HER2 agents in breast tumors overexpressing the targeted antigens.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP219595.RADr9l1wZK9vl7GGRN-zKSbz4kqDjLCoVssOgcAuANRzI130_provenance.